Although VEGFR1 has not previously been reported as a biomarker for imatinib in DFSP, Mathew P et al. noted that plasma levels of VEGFR1 link with imatinib therapy in prostate cancer [37], which may support our findings. The gene discussed is FLT1; the disease is prostate carcinoma.